中枢神経系原発リンパ腫アップデート
中枢神経系原発リンパ腫 (PCNSL) は高齢者に多く発生し, 近年増加傾向にあり, 脳腫瘍の4.9%を占める. びまん性大細胞型の組織型が多く, その中ではnon-GCB typeが多い. PCNSLではMYD88とCD79Bの変異の頻度が高く, BCRシグナル伝達経路の活性化が起こっているため, その経路にあるBTK阻害剤のチラブルチニブが再発・難治のPCNSLの治療薬として開発された. 放射線照射後の脳障害の軽減・回避と高齢者に対する治療が課題で, 治療成績の向上には新しい標準治療とされるR-MPV療法の普及や若年患者での末梢血幹細胞移植を伴う大量化学療法, そして再発時の適切な治療選択...
Saved in:
| Published in | 脳神経外科ジャーナル Vol. 31; no. 1; pp. 20 - 30 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人日本脳神経外科コングレス
01.01.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0917-950X 2187-3100 |
| DOI | 10.7887/jcns.31.20 |
Cover
| Abstract | 中枢神経系原発リンパ腫 (PCNSL) は高齢者に多く発生し, 近年増加傾向にあり, 脳腫瘍の4.9%を占める. びまん性大細胞型の組織型が多く, その中ではnon-GCB typeが多い. PCNSLではMYD88とCD79Bの変異の頻度が高く, BCRシグナル伝達経路の活性化が起こっているため, その経路にあるBTK阻害剤のチラブルチニブが再発・難治のPCNSLの治療薬として開発された. 放射線照射後の脳障害の軽減・回避と高齢者に対する治療が課題で, 治療成績の向上には新しい標準治療とされるR-MPV療法の普及や若年患者での末梢血幹細胞移植を伴う大量化学療法, そして再発時の適切な治療選択が肝要である. |
|---|---|
| AbstractList | 中枢神経系原発リンパ腫 (PCNSL) は高齢者に多く発生し, 近年増加傾向にあり, 脳腫瘍の4.9%を占める. びまん性大細胞型の組織型が多く, その中ではnon-GCB typeが多い. PCNSLではMYD88とCD79Bの変異の頻度が高く, BCRシグナル伝達経路の活性化が起こっているため, その経路にあるBTK阻害剤のチラブルチニブが再発・難治のPCNSLの治療薬として開発された. 放射線照射後の脳障害の軽減・回避と高齢者に対する治療が課題で, 治療成績の向上には新しい標準治療とされるR-MPV療法の普及や若年患者での末梢血幹細胞移植を伴う大量化学療法, そして再発時の適切な治療選択が肝要である. |
| Author | 山崎, 文之 |
| Author_xml | – sequence: 1 fullname: 山崎, 文之 organization: 広島大学病院脳神経外科 |
| BookMark | eNo9jz9Lw0AYxg-pYKxd_B6J792b5O4GByn-g4KLgttxSa7aUKMkXVw9RAcpOIlLhYKL4lQEUb_NqfFj2KK4PA_8ht_Ds0gaxXFhCFmmEHAh-EqeFlWANGAwRzxGBfeRAjSIB5JyX0awv0BaVZUDADKMgaNH8OPl6Ws0ru9H9fNVPXn7HN7Vt6_OPjg7cfb6-_zRnY2dtc7eOHvh7Luzl0tkvqv7lWn9dZPsbazvtrf8zs7mdnut4-eMTcdZkokIMxSpSFjM4yiUHCDiVIKglBtmdGrCrtYxZcATZqYMZRZCFmEcS4FNsvrrzauBPjDqpOwd6fJU6XLQS_tGzf4qpIrOgsE_Tw91qXKNP2hsYg8 |
| ContentType | Journal Article |
| Copyright | 2022 日本脳神経外科コングレス |
| Copyright_xml | – notice: 2022 日本脳神経外科コングレス |
| DOI | 10.7887/jcns.31.20 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2187-3100 |
| EndPage | 30 |
| ExternalDocumentID | article_jcns_31_1_31_20_article_char_ja |
| GroupedDBID | 2WC ALMA_UNASSIGNED_HOLDINGS JSF KQ8 OK1 RJT |
| ID | FETCH-LOGICAL-j2287-2bd853d38c8b2676549700571908117e2eace4faa61207b2e17e39d40d5366983 |
| ISSN | 0917-950X |
| IngestDate | Wed Sep 03 06:30:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2287-2bd853d38c8b2676549700571908117e2eace4faa61207b2e17e39d40d5366983 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jcns/31/1/31_20/_article/-char/ja |
| PageCount | 11 |
| ParticipantIDs | jstage_primary_article_jcns_31_1_31_20_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20220100 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 20220100 |
| PublicationDecade | 2020 |
| PublicationTitle | 脳神経外科ジャーナル |
| PublicationTitleAlternate | 脳外誌 |
| PublicationYear | 2022 |
| Publisher | 一般社団法人日本脳神経外科コングレス |
| Publisher_xml | – name: 一般社団法人日本脳神経外科コングレス |
| References | 26) Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R : Phase Ⅰ/Ⅱ study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 23 : 122-133, 2021. 5) Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 (Supple 1) : 9-102, 2017. 28) Rubenstein J, Ferreri AJ, Pittaluga S : Primary lymphoma of the central nervous system : epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma 49 Suppl 1 : 43-51, 2008. 14) Gritsch D, Mrugala MM, Marks LA, Mangipudi K, Neal M, Wingerchuk DM, O'Carroll CB : Is autologous stem cell transplantation a safe and effective alternative to whole brain radiation as consolidation therapy in patients with primary central nervous system lymphoma? : a critically appraised topic. Neurologist 26 : 137-142, 2021. 2) Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM : Primary central nervous system lymphoma : the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24 : 5711-5715, 2006. 24) Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Kinoshita M, Nagane M, Arakawa Y, Yoshimoto K, Shibahara I, Shinojima N, Asano K, Tsurubuchi T, Sasaki H, Asai A, Sasayama T, Momii Y, Sasaki A, Katayama H, Fukuda H : Randomized phase Ⅲ study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma : JCOG1114C. J Clin Oncol 38 (15_suppl) : 2500, 2020. 19) Kolakshyapati M, Adhikari RB, Karlowee V, Takayasu T, Nosaka R, Amatya VJ, Takeshima Y, Akiyama Y, Sugiyama K, Kurisu K, Yamasaki F : Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma : a novel diagnostic and specific prognostic indicator. J Neurosurg 128 : 667-678, 2018. 17) Herrlinger U, Schafer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M : Early whole brain radiotherapy in primary CNS lymphoma : negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143 : 1815-1821, 2017. 13) Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F ; International Extranodal Lymphoma Study Group (IELSG) : High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 374 : 1512-1520, 2009. 20) Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC, Hsu HC, Tien HF, Cheng AL : Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12 : 1152-1156, 2006. 27) Owen C, Berinstein NL, Christofides A, Sehn LH : Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol 26 : e233-e240, 2019. 7) Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A : A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas : analysis of 83 cases. Blood 107 : 190-196, 2006. 18) Kickingereder P, Wiestler B, Sahm F, Heiland S, Roethke M, Schlemmer HP, Wick W, Bendszus M, Radbruch A : Primary central nervous system lymphoma and atypical glioblastoma : multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology 272 : 843-850, 2014. 15) Grommes C, DeAngelis LM : Primary CNS lymphoma. J Clin Oncol 35 : 2410-2418, 2017. 3) Alnahhas I, Jawish M, Alsawas M, Zukas A, Prokop L, Murad MH, Malkin M : Autologous stem-cell transplantation for primary central nervous system lymphoma : systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 19 : e129-e141, 2019. 23) Milgrom SA, Yahalom J : The role of radiation therapy in the management of primary central nervous system lymphoma. Leuk Lymphoma 56 : 1197-1204, 2015. 34) Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, Takaba J, Tominaga A, Hanaya R, Yoshioka H, Hama S, Ito Y, Kajiwara Y, Yahara K, Saito T, Thohar MA : Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235 : 985-991, 2005. 12) Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 : 266-272, 2003. 35) Yamasaki F, Takayasu T, Nosaka R, Amatya VJ, Doskaliyev A, Akiyama Y, Tominaga A, Takeshima Y, Sugiyama K, Kurisu K : Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis : a characteristic of malignant lymphoma. J Neurosurg 122 : 1370-1379, 2015. 4) Barajas RF, Politi LS, Anzalone N, Schoder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS : Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma : guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 23 : 1056-1071, 2021. 16) Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004. 30) Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T : Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100 : 1842-1847, 2009. 36) 山崎文之, 高安武志, 杉山一彦 : 中枢神経系原発悪性リンパ腫. 杉山一彦, 橋本直哉編 : 脳神経外科速報2020年増刊 悪性脳腫瘍のすべて. 大阪, メディカ出版, 2020, pp.251-258. 6) Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K : Mutational analysis of primary central nervous system lymphoma. Oncotarget 5 : 5065-5075, 2014. 10) Eloranta S, Branvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G, Ekstrom-Smedby K : Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol 100 : 61-68, 2018. 9) Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA : Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127 : 869-881, 2016. 29) Sakata A, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Dodo T, Arakawa Y, Takahashi JC, Miyamoto S, Togashi K : Primary central nervous system lymphoma : is absence of intratumoral hemorrhage a characteristic finding on MRI? Radiol Oncol 49 : 128-134, 2015. 8) Canovi S, Campioli D : Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms : A systematic review. Diagn Cytopathol 44 : 841-856, 2016. 11) Farrall AL, Smith JR : Changing incidence and survival of primary central nervous system lymphoma in Australia : a 33-year national population-based study. Cancers (Basel) 13 : 403, 2021. 1) Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F ; International Primary CNS Lymphoma Collaborative Group : Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 : 5034-5043, 2005. 32) Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM : Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21 : 922-926, 2015. 31) van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ : Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry B Clin Cytom 94 : 928-934, 2018. 33) Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang B |
| References_xml | – reference: 10) Eloranta S, Branvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G, Ekstrom-Smedby K : Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol 100 : 61-68, 2018. – reference: 27) Owen C, Berinstein NL, Christofides A, Sehn LH : Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol 26 : e233-e240, 2019. – reference: 30) Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T : Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100 : 1842-1847, 2009. – reference: 6) Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K : Mutational analysis of primary central nervous system lymphoma. Oncotarget 5 : 5065-5075, 2014. – reference: 5) Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 (Supple 1) : 9-102, 2017. – reference: 31) van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ : Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry B Clin Cytom 94 : 928-934, 2018. – reference: 28) Rubenstein J, Ferreri AJ, Pittaluga S : Primary lymphoma of the central nervous system : epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma 49 Suppl 1 : 43-51, 2008. – reference: 19) Kolakshyapati M, Adhikari RB, Karlowee V, Takayasu T, Nosaka R, Amatya VJ, Takeshima Y, Akiyama Y, Sugiyama K, Kurisu K, Yamasaki F : Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma : a novel diagnostic and specific prognostic indicator. J Neurosurg 128 : 667-678, 2018. – reference: 26) Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R : Phase Ⅰ/Ⅱ study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 23 : 122-133, 2021. – reference: 16) Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004. – reference: 23) Milgrom SA, Yahalom J : The role of radiation therapy in the management of primary central nervous system lymphoma. Leuk Lymphoma 56 : 1197-1204, 2015. – reference: 25) Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A : Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma : final results and long-term outcome. J Clin Oncol 31 : 3971-3979, 2013. – reference: 9) Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA : Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127 : 869-881, 2016. – reference: 35) Yamasaki F, Takayasu T, Nosaka R, Amatya VJ, Doskaliyev A, Akiyama Y, Tominaga A, Takeshima Y, Sugiyama K, Kurisu K : Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis : a characteristic of malignant lymphoma. J Neurosurg 122 : 1370-1379, 2015. – reference: 14) Gritsch D, Mrugala MM, Marks LA, Mangipudi K, Neal M, Wingerchuk DM, O'Carroll CB : Is autologous stem cell transplantation a safe and effective alternative to whole brain radiation as consolidation therapy in patients with primary central nervous system lymphoma? : a critically appraised topic. Neurologist 26 : 137-142, 2021. – reference: 29) Sakata A, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Dodo T, Arakawa Y, Takahashi JC, Miyamoto S, Togashi K : Primary central nervous system lymphoma : is absence of intratumoral hemorrhage a characteristic finding on MRI? Radiol Oncol 49 : 128-134, 2015. – reference: 17) Herrlinger U, Schafer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M : Early whole brain radiotherapy in primary CNS lymphoma : negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143 : 1815-1821, 2017. – reference: 24) Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Kinoshita M, Nagane M, Arakawa Y, Yoshimoto K, Shibahara I, Shinojima N, Asano K, Tsurubuchi T, Sasaki H, Asai A, Sasayama T, Momii Y, Sasaki A, Katayama H, Fukuda H : Randomized phase Ⅲ study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma : JCOG1114C. J Clin Oncol 38 (15_suppl) : 2500, 2020. – reference: 4) Barajas RF, Politi LS, Anzalone N, Schoder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS : Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma : guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 23 : 1056-1071, 2021. – reference: 2) Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM : Primary central nervous system lymphoma : the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24 : 5711-5715, 2006. – reference: 7) Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A : A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas : analysis of 83 cases. Blood 107 : 190-196, 2006. – reference: 22) Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C : The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20 : 687-694, 2018. – reference: 8) Canovi S, Campioli D : Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms : A systematic review. Diagn Cytopathol 44 : 841-856, 2016. – reference: 3) Alnahhas I, Jawish M, Alsawas M, Zukas A, Prokop L, Murad MH, Malkin M : Autologous stem-cell transplantation for primary central nervous system lymphoma : systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 19 : e129-e141, 2019. – reference: 20) Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC, Hsu HC, Tien HF, Cheng AL : Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12 : 1152-1156, 2006. – reference: 15) Grommes C, DeAngelis LM : Primary CNS lymphoma. J Clin Oncol 35 : 2410-2418, 2017. – reference: 1) Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F ; International Primary CNS Lymphoma Collaborative Group : Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 : 5034-5043, 2005. – reference: 33) Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC : Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370 : 2286-2294, 2014. – reference: 18) Kickingereder P, Wiestler B, Sahm F, Heiland S, Roethke M, Schlemmer HP, Wick W, Bendszus M, Radbruch A : Primary central nervous system lymphoma and atypical glioblastoma : multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology 272 : 843-850, 2014. – reference: 34) Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, Takaba J, Tominaga A, Hanaya R, Yoshioka H, Hama S, Ito Y, Kajiwara Y, Yahara K, Saito T, Thohar MA : Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235 : 985-991, 2005. – reference: 36) 山崎文之, 高安武志, 杉山一彦 : 中枢神経系原発悪性リンパ腫. 杉山一彦, 橋本直哉編 : 脳神経外科速報2020年増刊 悪性脳腫瘍のすべて. 大阪, メディカ出版, 2020, pp.251-258. – reference: 13) Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F ; International Extranodal Lymphoma Study Group (IELSG) : High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 374 : 1512-1520, 2009. – reference: 21) Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH : Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31 : 833-843 e5, 2017. – reference: 32) Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM : Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21 : 922-926, 2015. – reference: 11) Farrall AL, Smith JR : Changing incidence and survival of primary central nervous system lymphoma in Australia : a 33-year national population-based study. Cancers (Basel) 13 : 403, 2021. – reference: 12) Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 : 266-272, 2003. |
| SSID | ssj0003236073 ssib023160918 ssib002223908 ssib000937641 |
| Score | 2.2779667 |
| Snippet | 中枢神経系原発リンパ腫 (PCNSL) は高齢者に多く発生し, 近年増加傾向にあり, 脳腫瘍の4.9%を占める. びまん性大細胞型の組織型が多く, その中ではnon-GCB typeが多い. PCNSLではMYD88とCD79Bの変異の頻度が高く, BCRシグナル伝達経路の活性化が起こっているため,... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 20 |
| SubjectTerms | diffuse large B cell lymphoma primary central nervous system lymphoma R-MPV tirabrutinib whole brain radiotherapy |
| Title | 中枢神経系原発リンパ腫アップデート |
| URI | https://www.jstage.jst.go.jp/article/jcns/31/1/31_20/_article/-char/ja |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 脳神経外科ジャーナル, 2022, Vol.31(1), pp.20-30 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9RAFA-1XryIouI3PTjHrZOZyWTmmFlTiqIgtLC3sJPEwx6qSIvg0SB6EMGTeKlQ8KJ4KoKo_03U9c_wvZdkN2091IVleHmZvHkfCfObjzcbBDeUsaEPtRl4pSQMUEIFn1TkB5joaIzMTUGJwnfv6fVNdXsUjZZOPOlnl2z71fzpP_NKFokq8CCumCX7H5GdCQUG0BBfKCHCUB4rxixVzBmW3GKpZjZliWBpzJIIaSBcxMyQCMmcYylcpsyuIcda5hKWSmYkSzoCqjWEDVlqmIlY4ogjSDLdMrM6ccfpCDfsOKYPeUmUIuFHdYMmFLOabsXULjUHRrW6ySPCZ2rPFotQjAvxh4RCK-HFIZ9oUg9at8y4_gyHEIdmOFpfGk76glPJc6CdS1GsdaSLRjtsRJUTcqFGT4BZSAzpqQXMlQcjABzeWTnsOLY_qxriijgfNd0r8QBE4VQw5_1Op-36-h9X24PwHhZplqwO93K4ARR7uRxeXhmudk8cODW8fSczrJTJMAuxEDzr-JjTl01gYHFSxDHtb7hzv4fLAbTqPk4GEGnnh0DBmECDpWY2mSmF1LzZzdE5oDkKGFW9OVcUYN4EBj3dhknCcBtngtPt4GslabQ7GyxNxucC-fPr59-7e9MPu9Mvr6b733-9fj99962uPtbVfl29-fP8U_1sr66qunpbVy_q6kddvTwfbK6lG8P1QftXIoOJEOB-4QvApYU0ufFCxzpSNsY8bIDDmGldCsAfpXowHgPg57EXJfCkLRQvIqm1NfJCsLz1cKu8GKyouAhFnueGxzmmlRuTl3jIks_52PtSXAp0Y2P2qDkvJjtmLC4v-uCV4NT8s7kaLG8_3imvAVTe9tcprH8BbD6Qlw |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E4%B8%AD%E6%9E%A2%E7%A5%9E%E7%B5%8C%E7%B3%BB%E5%8E%9F%E7%99%BA%E3%83%AA%E3%83%B3%E3%83%91%E8%85%AB%E3%82%A2%E3%83%83%E3%83%97%E3%83%87%E3%83%BC%E3%83%88&rft.jtitle=%E8%84%B3%E7%A5%9E%E7%B5%8C%E5%A4%96%E7%A7%91%E3%82%B8%E3%83%A3%E3%83%BC%E3%83%8A%E3%83%AB&rft.au=%E5%B1%B1%E5%B4%8E%2C+%E6%96%87%E4%B9%8B&rft.date=2022-01-01&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA%E6%97%A5%E6%9C%AC%E8%84%B3%E7%A5%9E%E7%B5%8C%E5%A4%96%E7%A7%91%E3%82%B3%E3%83%B3%E3%82%B0%E3%83%AC%E3%82%B9&rft.issn=0917-950X&rft.eissn=2187-3100&rft.volume=31&rft.issue=1&rft.spage=20&rft.epage=30&rft_id=info:doi/10.7887%2Fjcns.31.20&rft.externalDocID=article_jcns_31_1_31_20_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0917-950X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0917-950X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0917-950X&client=summon |